Related Experiment Video
Updated: Nov 6, 2025
11:15
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
Published on: September 20, 2016
24.7K
Summary
Tumor mutation burden (TMB) shows promise as a biomarker for predicting responses to immune checkpoint inhibitors. Further research is needed to refine TMB for widespread use across diverse cancers and patient groups.
Area of Science:
- Oncology
- Immunotherapy
- Biomarker Discovery
Background:
- Immune checkpoint inhibitors (ICIs) are revolutionizing cancer treatment.
- Tumor mutation burden (TMB) is emerging as a predictive biomarker for ICI response.
- Current TMB assays require standardization for broad clinical application.
Discussion:
- TMB reflects the number of mutations within a tumor's genome.
- Higher TMB may correlate with increased neoantigen presentation, enhancing immune recognition.
- Factors like tumor type, sequencing methods, and analytical pipelines influence TMB values.
Key Insights:
- TMB is a valuable but imperfect biomarker for ICI therapy.
- Refining TMB measurement and interpretation is crucial for clinical utility.
- Standardization across different platforms and tumor types is essential.
Outlook:
- Further research will focus on harmonizing TMB assessment methodologies.
- Development of more robust TMB signatures will improve patient stratification.
- Optimized TMB biomarkers will enhance the efficacy and accessibility of immunotherapy.
